Active Ingredient(s): Ruxolitinib Phosphate
FDA Approved: * September 21, 2021
Pharm Company: * INCYTE CORP
Category: Cancer

Ruxolitinib, sold under the brand names Jakafi and Jakavi, is a medication for the treatment of intermediate or high-risk myelofibrosis,[1] a type of myeloproliferative disorder that affects the bone marrow;[5][6] polycythemia vera (PCV), when there has been an inadequate response to or intolerance of hydroxyurea;[1][7] and steroid-refractory acute graft-versus-host disease.[1] It was developed and... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Opzelura 15 mg/g Topical Cream
NDC: 50881-007
Incyte Corporation

Related Brands

Drugs with the same active ingredients